KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Mistletoe extract in patients with advanced pancreatic cancer: Health-related quality of life in a double-blind, randomized, placebo-controlled trial (MISTRAL).

Kathrin Wode, Ove Björ, Reinhild Klein, Nils Oskar Elander, Per Fransson, Roger Henriksson, Lena Sharp, Ursula Scheibling, Birgit Johansson, Johanna Hök Nordberg, Gunver Sophia Kienle

Palliat Med 40(7) 1059-1076

PMID42059487
PMCIDPMC13323928
DOI10.1177/02692163261437609
发表日期2026-04-30
入排依据:The study meets criteria for oncology, human, randomized, Phase III, and original trial with drug intervention. However, it is ineligible because the reported efficacy endpoints are quality-of-life, weight, cost, and biomarker outcomes. No primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) is reported.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:生活质量量表图。
摘要

摘要

BACKGROUND: Mistletoe extract is a widespread complementary therapy mainly used for quality-of-life improvement in cancer patients. Advanced pancreatic cancer is associated with poor quality of life and better therapies for symptomatic relief are highly needed. AIM: MISTRAL aimed to assess the impact of mistletoe extract on quality of life, body weight, observed costs and blood biomarkers in patients with advanced pancreatic cancer. DESIGN: MISTRAL was an investigator-initiated, phase III, randomized, double-blind, placebo-controlled, parallel-group, superiority, multicenter, clinical trial with a nested biomarker study. Registration EudraCT 2014-004552-64, NCT02948309. SETTING AND PARTICIPANTS: At 9 oncology centers, 290 participants were randomized to standard treatment (palliative chemotherapy or best supportive care) plus subcutaneous mistletoe extract or placebo. Main inclusion criteria were advanced pancreatic cancer, performance status 0-2, main exclusion criteria neuroendocrine pancreatic tumor. EORTC-QLQ-C30, EORTC-QLQ-PAN26, body weight, cost parameters and biomarkers were assessed from baseline up until 9 months. RESULTS: No statistically significant differences for quality of life and weight were evident between treatment arms. Parameters for observed costs for supportive and inpatient care (days at hospital, parenteral nutrition infusions, nutritional supplement drinks, number of visits of palliative home care teams, symptom-relieving medication) were similar in both arms. Thus, calculation of costs was not performed. No effect on explored biomarkers (differential blood count, lymphocyte subpopulations, C-reactive protein, albumin and Ca19-9) was found except for a statistically significant increase of eosinophils in the mistletoe arm without association to clinical effect. CONCLUSIONS: Since no benefit was observed, there is no clinical reason to recommend mistletoe extract in patients with advanced pancreatic cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Flowchart of trial participants. 1 Urticaria (known side-effect from mistletoe extract).
非 KM Figure
Figure 2.Mean changes in quality-of-life and weight change by treatment arm and visit. Changes in quality of life scores for five of six 1 functional scales and nine symptom scales compared to baseline scores (95% confidence interval), calculated using mixed model regression. Data was collected using the EORTC-QLOQ-C30 questionnaire. Blue mistletoe extract, red placebo. Higher scores indicate better quality of life for physical, role, emotional, cognitive and social functioning Lower scale indicate better quality of life for fatigue, appetite loss, nausea and vomiting, pain, dyspnea, insomnia, constipation, diarrhea and financial difficulties. p -value from test of the treatment effect by Satterthwaite’s method is shown in the figure. Marginal mean weight change (95% CI) in percent from weight registered at baseline visit estimated from mixed model. 1 Results for the functional scale global health have been published in (Wode, 2024 #5018).
非 KM Figure